Tesamorelin
Egrifta · GHRH analog
The Ground Truth Score
four plain questions, never one numberProven
Bottom line
The grown-up in the room: FDA-approved, studied in proper randomized trials, with a known and manageable risk profile, the standard every wellness peptide on this site is measured against.
Does the science back it?
Do real people feel it?
Is it safe?
Could it be placebo?
"Do real people feel it?" is anecdote, not proof, weighted up because the science is thin, never because it beats a trial. And "could it be placebo?" is not an insult: if you feel better, that's real to you. The point is only to know whether you're paying peptide prices for an expectation.
Why is the evidence this thin? It's mostly economics →
Dose at a glance
full dosing ↓Here we can cite an actual approved dose, not a rumor: 2 mg subcutaneously daily (original Egrifta), or 1.28 mg subcutaneously once daily (EGRIFTA WR, the room-temperature formulation.
Reported, not prescribed. Verify your vial and your math.
First documented human use
Well-documented. Studied in registrational human trials leading to FDA approval in 2010 for HIV-associated lipodystrophy; the room-temperature formulation EGRIFTA WR was FDA-approved in March 2025.
The pitch
What people claim it does
Stated plainly and neutrally, exactly as you'll hear it. I grade each one below.
- Reduces visceral (deep abdominal) fat.
- Lowers liver fat and may improve fatty-liver disease.
- Raises growth hormone and IGF-1 relatively physiologically; reported to support sleep.
The data behind each bullet
What actually backs it
Reduces visceral fat.
Phase 3 randomized trials showed ~15% visceral-fat reduction over 26 weeks versus placebo, the basis for FDA approval.
Phase 3 registration trials ↗Lowers liver fat.
In an HIV-population RCT, 2 mg daily for 12 months cut hepatic fat fraction ~37% versus placebo, with less fibrosis progression. Non-HIV NAFLD trials are ongoing.
NAFLD randomized trial ↗Improves cognition.
Worth flagging the negative result honestly: a January 2025 RCT did NOT show significant cognitive benefit over placebo, despite earlier promise. I grade what the trials actually found.
Cognition RCT (2025), negative ↗Mechanism
How it's assumed to work
Assumed · theoretical pathway
Established, not assumed: tesamorelin is a GHRH analog, it tells the pituitary to release the body's own growth hormone in a relatively natural, pulsatile way, which reduces visceral fat. Proven in human trials.
Dosing & handling
What users and clinicians report
Here we can cite an actual approved dose, not a rumor: 2 mg subcutaneously daily (original Egrifta), or 1.28 mg subcutaneously once daily (EGRIFTA WR, the room-temperature formulation. 0.16 mL reconstituted). Some users run a lower evening dose for sleep and liver goals rather than the full visceral-fat dose. Prescription and physician monitoring are the norm, and the point.
Even with an approved compound, dose and monitoring belong with a prescriber. The numbers here are the label, not personal medical advice.
Timing & food
2 mg daily (or 1.28 mg daily for EGRIFTA WR), typically at night and on an empty stomach, because glucose and insulin blunt growth-hormone release, and the goal is to ride the body's natural nighttime GH pulse.
Half-life
Short, tesamorelin clears quickly, which is why it's dosed daily. The newer EGRIFTA WR formulation keeps the once-daily cadence but adds room-temperature stability and a smaller injection volume.
Reconstitution sensitivity
A pharmaceutical product with real manufacturer quality control, a major advantage over gray-market peptides. The original needs refrigeration and careful reconstitution; the room-temperature WR version is more forgiving (room-temp storage, lower injection volume).
Real-world signal
What people actually report
Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.
Volume
Moderate, more than MOTS-c, less than BPC-157; deep off-label threads plus on-label patient reviews.
Consistency
Visceral-fat loss and IGF-1 rise converge and are self-policing, the community warns it hits visceral, not subcutaneous, fat.
Source credibility
Unusually checkable, a real FDA/clinical spine exists, but we keep the community-signal grade separate from that halo.
- Users and patients consistently report visceral and abdominal fat reduction, and here it is backed by trials, not just stories.
- Improved sleep and body composition are common reports.
- Injection-site reactions, joint aches, and fluid retention are the usual complaints, matching the trial data.
Placebo risk, Low
Its headline effect, visceral fat, is measured on a scan in controlled trials. This is the one where the result is real, not a feeling.
Risk panel
What could go wrong
Adverse events
Well-characterized from registration trials: injection-site reactions, joint pain, peripheral edema, muscle pain. These are documented frequencies, not guesses.
Theoretical concerns
Raises IGF-1, so cancer screening and monitoring are advised; can affect glucose metabolism. Don't stack with other GH-promoting peptides without physician oversight.
Contraindications
Active malignancy; pregnancy; disrupted pituitary axis. Monitor IGF-1, glucose and PSA.
Honest unknowns
Long-term outcomes in non-HIV populations are still being studied; the cognitive question is effectively answered as negative.
Confound watch
Because it's prescribed and monitored, tesamorelin is less confounded than the wellness peptides, but body-composition users still typically combine it with training, GLP-1s or TRT, so isolate the variable if you want to know what it's doing for you.
History
Discovery → first use → status
- 2010FDA approves tesamorelin (Egrifta) for HIV-associated lipodystrophy.
- 2010sRCTs extend the evidence to liver fat (NAFLD) in HIV populations.
- Jan 2025Cognition RCT reports no significant benefit, an honest negative.
- Mar 2025EGRIFTA WR, a room-temperature, reduced-volume formulation (1.28 mg SC once daily), FDA-approved (available Sept 2025).
Verification
The COA standard, applied
Pharmaceutical tesamorelin (Egrifta / EGRIFTA WR) is FDA-regulated and arrives with manufacturer quality assurance, a major advantage over gray-market compounds. If sourced from a compounding pharmacy instead, apply the full COA standard and confirm the pharmacy's licensure.
The full verification standard →Sources
Where this comes from
The four lenses reflect the evidence and the real-world record as of the last review and will change as data arrives. Real-world signal and reported feedback are anecdote, not proof. Nothing here is medical advice or a prescription.